Solid Biosciences Says FDA Grants Fast Track Designation For Gene Therapy Candidate SGT-003
Life sciences company Solid Biosciences Inc. (SLDB) announced Thursday that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for SGT-003, the company's next-generation Duchenne muscular dystrophy gene therapy candidate.
Drug Administration Solid Biosciences Inc Solid Biosciences Fast Track Designation Us Food And Drug Administration Duchenne Muscular Dystrophy
Source: rttnews.com